Management’s guidance upgrade for FY19
13/01/20 -"Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for the forecast years. Combined with robust operational ..."
Pages
68
Language
English
Published on
13/01/20
You may also be interested by these reports :
17/09/20
Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma ...
17/09/20
Merck confirmed our positive view on the company. As expected, management confirmed the FY 2022 guidance and put some nice colour on 2021. The ...
09/09/20
In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on ...
07/09/20
Surprisingly, Akebia’s oral HIF-PHI drug, Vadadustat, has shown heart safety concerns in a phase III study for non-dialysis CKD-anaemic patients. ...